about
Infection control in gene therapy.High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells.Human immunodeficiency virus type 1 vectors efficiently transduce human hematopoietic stem cellsNonreciprocal packaging of human immunodeficiency virus type 1 and type 2 RNA: a possible role for the p2 domain of Gag in RNA encapsidation.Separable mechanisms of attachment and cell uptake during retrovirus infection.Infection control for gene therapy: a busy physician's primer.Lentivirus and foamy virus vectors: novel gene therapy tools.Lentiviral-mediated delivery of siRNAs for antiviral therapy.Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays.The inside out of lentiviral vectorsSuppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2.Optimal modes and targets of gene therapy in transplantation.Therapeutic potential of retroviral RNAi vectors.Heterologous human immunodeficiency virus type 1 lentiviral vectors packaging a simian immunodeficiency virus-derived genome display a specific postentry transduction defect in dendritic cells.Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD4+ cellsEnhancing siRNA effects in T cells for adoptive immunotherapy.Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytesSelective killing of HIV-1-positive macrophages and T cells by the Rev-dependent lentivirus carrying anthrolysin O from Bacillus anthracis.Recent advances in delivery systems for anti-HIV1 therapy.Polymers for DNA delivery.Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.Multiple Gag domains contribute to selective recruitment of murine leukemia virus (MLV) Env to MLV virions.Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent.Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1.Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells.Inhibition of hepatitis B virus X gene expression by novel DNA enzymes.Spleen necrosis virus-derived C-type retroviral vectors for gene transfer to quiescent cells.Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap.Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system.Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors.Improved titers of HIV-based lentiviral vectors using the SRV-1 constitutive transport element.Retrovirus molecular conjugates: a versatile and efficient gene transfer vector system for primitive human hematopoietic progenitor cells.Revisiting complexation between DNA and polyethylenimine: does the disulfide linkage play a critical role in promoting gene delivery?[Advances of lentiviral vectors].
P2860
Q33722265-49BCDDF1-94AB-47FA-875A-752488712741Q33785302-72A46851-CBA9-437D-93B4-EFC82B6E9192Q33785609-0FA69826-E4CE-4255-BEEA-4D9B16DDF929Q33785662-DC86A123-620D-4C9E-9FFE-7AE509EC6374Q33787363-CF10A67A-0B90-4FC0-8AC6-BEEB81F5BE87Q34144013-AB49F1BA-B650-4B7D-8DBA-28A1FEC99690Q34452109-6D006D8F-ED3D-453C-8325-EC6932CE6E8EQ34482299-20F601DB-C75B-41D7-993F-EC431CF50021Q34489422-753856BC-948E-4770-836D-9EB72177F57BQ34633466-94CD66C5-1075-4C44-9A15-BB82DC487B20Q35409847-3F12A579-C240-4965-9AE4-032120860D32Q35583526-0F7FD0AE-F136-460C-8629-19A7BD2B18D6Q35684854-89EC9C97-D6B0-4A40-94E2-814F2C5A35C1Q35803032-8E2768C0-32D5-4DF7-BCAB-596245FBDEACQ35882018-B4B8CF56-4AD9-41D7-B279-9E520459EF10Q36328391-50FC3413-823D-47B6-A8F2-718BA6D803EAQ36368207-24BDD70C-F4C6-4964-B7D7-0B2BDCD58C6EQ36667599-FD5D3D10-0E7C-43C8-8D23-9442C2127090Q36761854-7A42D735-20FA-41DB-BED9-CEA84A073E13Q37002661-E6696A2F-4CD2-48B8-AC29-FB464549B2E4Q38848060-41E526BC-D93C-44EF-93B1-FCEA7A179962Q39139624-D398723F-1BC1-4851-AF48-69410FD5283AQ39244695-4B3391AE-5698-45BB-B2BF-82165DB22600Q39550293-AFEA18E5-5FF1-4D57-8275-D548B5DA8D87Q39577503-02571E05-58BF-426C-B83F-214ADAA4C64FQ39595638-43DE78D0-7CA0-4517-9C88-5C94B3538273Q40828317-FC2930C0-5EBD-46C0-BC0E-C03B4423A6F4Q40876326-2B9848F5-69FB-4B87-8A18-09E601E4DF98Q43600028-74D443D3-0489-4AE7-8D2A-E2C3788BA437Q45746979-476C704C-47D2-4C0E-B4D0-DFBD1B363018Q45855831-278656B1-B062-4BAE-8631-D061C8167F5DQ45870690-CD7DE98A-D7B2-4D5E-9BEF-580B77B7B155Q45888520-F2D3BB99-F109-46A9-B033-1D24BB161A60Q51049222-EC891616-DABE-4E07-9780-AE44AD7AA3EDQ52980185-31AEB4FC-56FE-405A-9775-8573BDE5A300
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of HIV vectors for anti-HIV gene therapy.
@en
Development of HIV vectors for anti-HIV gene therapy.
@nl
type
label
Development of HIV vectors for anti-HIV gene therapy.
@en
Development of HIV vectors for anti-HIV gene therapy.
@nl
prefLabel
Development of HIV vectors for anti-HIV gene therapy.
@en
Development of HIV vectors for anti-HIV gene therapy.
@nl
P2093
P2860
P356
P1476
Development of HIV vectors for anti-HIV gene therapy.
@en
P2093
Poeschla E
Wong-Staal F
P2860
P304
11395-11399
P356
10.1073/PNAS.93.21.11395
P407
P577
1996-10-01T00:00:00Z